169 related articles for article (PubMed ID: 2468280)
1. Comparison of prostate-specific antigen and prostatic acid phosphatase in the management of prostatic cancer.
Turkes A; Nott J; Turkes AO; Griffiths K
Am J Clin Oncol; 1988; 11 Suppl 2():S77-9. PubMed ID: 2468280
[TBL] [Abstract][Full Text] [Related]
2. Prostate-specific antigen (PSA) in the management of 500 prostatic patients.
Guillet J; Role C; Duc AT; François H
Am J Clin Oncol; 1988; 11 Suppl 2():S61-2. PubMed ID: 2468274
[TBL] [Abstract][Full Text] [Related]
3. Systematic association of PAP and PSA determinations to bone scintigraphy in prostatic cancer.
Fincker F; Sauvan R; Pasquier J
Am J Clin Oncol; 1988; 11 Suppl 2():S68-70. PubMed ID: 2468277
[TBL] [Abstract][Full Text] [Related]
4. Significance of PSA and PAP in patients with or without prostatic cancer.
Caty A; Gosselin P; Cazin JL; Dehaut JM; Adenis L
Am J Clin Oncol; 1988; 11 Suppl 2():S63-4. PubMed ID: 2468275
[TBL] [Abstract][Full Text] [Related]
5. Comparative experimental study of the serum prostate specific antigen and prostatic acid phosphatase in serially transplantable human prostatic carcinoma lines in nude mice.
Csapo Z; Brand K; Walther R; Fokas K
J Urol; 1988 Nov; 140(5):1032-8. PubMed ID: 2459419
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of prostate-specific antigen in prostate cancer.
Pons-Anicet D; Ramaioli A; Namer M; Krebs BP
Am J Clin Oncol; 1988; 11 Suppl 2():S71-4. PubMed ID: 2468278
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of changes in prostate-specific markers after endocrine treatment of stage D2 prostatic cancer.
Matzkin H; Eber P; Todd B; van der Zwaag R; Soloway MS
Cancer; 1992 Nov; 70(9):2302-9. PubMed ID: 1382828
[TBL] [Abstract][Full Text] [Related]
8. The usefulness of prostate-specific antigen and prostatic acid phosphatase in clinical practice.
Daver A; Soret JY; Coblentz Y; Allain YM; Cellier P; Chauveau P
Am J Clin Oncol; 1988; 11 Suppl 2():S53-60. PubMed ID: 2468273
[TBL] [Abstract][Full Text] [Related]
9. Prostate-specific antigen as a unique routine test in monitoring therapy for inoperable prostate cancer: comparison with radionuclide bone scan and prostatic acid phosphatase.
Barichello M; Gion M; Bonazza A; Delli Ponti US; Bolgan A; Contemori GP; Barioli P; Capitanio G; Pecori B; Omacini S
Eur Urol; 1995; 27(4):295-300. PubMed ID: 7544735
[TBL] [Abstract][Full Text] [Related]
10. Clinical usefulness of prostate-specific antigen and prostatic acid phosphatase in patients with prostatic cancer.
Filella X; Molina R; Jo J; Umbert B; Bedini JL; Ballesta AM
Tumour Biol; 1990; 11(6):289-94. PubMed ID: 1700860
[TBL] [Abstract][Full Text] [Related]
11. An evaluation of the immunochemical measurement of prostatic acid phosphatase and prostatic specific antigen in carcinoma of the prostate.
Siddall JK; Cooper EH; Newling DW; Robinson MR; Whelan P
Eur Urol; 1986; 12(2):123-30. PubMed ID: 2420600
[TBL] [Abstract][Full Text] [Related]
12. Prostate-specific antigen as a marker of adenocarcinoma of prostate.
Kellokumpu-Lehtinen P; Nurmi M; Koskinen P; Irjala K
Urol Res; 1989; 17(4):245-9. PubMed ID: 2475959
[TBL] [Abstract][Full Text] [Related]
13. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate.
Stamey TA; Yang N; Hay AR; McNeal JE; Freiha FS; Redwine E
N Engl J Med; 1987 Oct; 317(15):909-16. PubMed ID: 2442609
[TBL] [Abstract][Full Text] [Related]
14. Relative value of prostate-specific antigen and prostatic acid phosphatase in diagnosis and management of adenocarcinoma of prostate. Ohio State University experience.
Drago JR; Badalament RA; Wientjes MG; Smith JJ; Nesbitt JA; York JP; Ashton JJ; Neff JC
Urology; 1989 Oct; 34(4):187-92. PubMed ID: 2477931
[TBL] [Abstract][Full Text] [Related]
15. Is prostate-specific antigen the most useful marker for screening in prostate cancer?
Delaere KP; Van Dieijen-Visser MP; Gijzen AH; Brombacher PJ
Am J Clin Oncol; 1988; 11 Suppl 2():S65-7. PubMed ID: 2468276
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of prostate-specific antigen and prostatic acid phosphatase in untreated prostatic carcinoma and benign prostatic hyperplasia.
Bogdanowicz JF; Bentvelsen FM; Oosterom R; Schroeder FH
Scand J Urol Nephrol Suppl; 1991; 138():97-103. PubMed ID: 1723815
[TBL] [Abstract][Full Text] [Related]
17. [A comparison between prostate-acid-phosphatase and prostate-specific antigen in the diagnosis of prostatic carcinoma].
Bentvelsen FM; Bogdanowicz JF; Oosterom R; Schröder FH
Ned Tijdschr Geneeskd; 1990 Aug; 134(33):1596-600. PubMed ID: 1697651
[TBL] [Abstract][Full Text] [Related]
18. Clinical utility of prostatic specific antigen and prostatic acid phosphatase serum levels in monitoring prostate cancer.
Morote J; Ruibal A; Palou J; de Torres JA; Soler-Roselló A
Int J Biol Markers; 1988; 3(1):23-8. PubMed ID: 2470838
[TBL] [Abstract][Full Text] [Related]
19. Prostate-specific antigen in prostatic cancer.
Baron JC; Peyret C; Leroy M; Teillac P; Najean Y; Le Duc A
Am J Clin Oncol; 1988; 11 Suppl 2():S75-6. PubMed ID: 2468279
[TBL] [Abstract][Full Text] [Related]
20. Comparative study of the clinical usefulness of prostate specific antigen and prostatic acid phosphatase in prostatic disease.
Buamah PK; Johnson P; Skillen AW
Br J Urol; 1988 Dec; 62(6):581-3. PubMed ID: 2464396
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]